Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab
Condition(s):Neovascular Age-related Macular DegenerationLast Updated:January 30, 2024Completed
Hide Studies Not Open or Pending
Condition(s):Neovascular Age-related Macular DegenerationLast Updated:January 30, 2024Completed
Condition(s):Age-related Macular Degeneration; Age-related MaculopathyLast Updated:November 7, 2023Active, not recruiting
Condition(s):Macular DegenerationLast Updated:June 24, 2009Completed
Condition(s):Dry Age-related Macular DegenerationLast Updated:April 8, 2021Withdrawn
Condition(s):Neovascular Age-related Macular DegenerationLast Updated:April 5, 2018Completed
Condition(s):Age-Related Macular DegenerationLast Updated:January 3, 2024Recruiting
Condition(s):Macular DegenerationLast Updated:March 21, 2022Completed
Condition(s):Wet Macular DegenerationLast Updated:December 29, 2023Recruiting
Condition(s):Age Related Macular DegenerationLast Updated:September 2, 2021Completed
Condition(s):Age-Related Macular DegenerationLast Updated:January 8, 2010Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.